Heather L. McArthur, Kathleen M. Mahoney, Patrick G. Morris, Sujata Patil, Lindsay M. Jacks, Jane Howard, Larry Norton and Clifford A. Hudis Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer Cancer 117
Article first published online: 16 JUN 2011 | DOI: 10.1002/cncr.26171
Although several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy, the benefit for women with small, node-negative HER2-positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. This retrospective, single-institution, sequential cohort study indicates that women with small, node-negative, HER2+ primary breast cancers likely derive significant benefit from adjuvant trastuzumab with chemotherapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field